Loading quotes...
Forecast
The analysts' average price target is €65.32 (+4.60%). The median is €68.56 (+9.78%).
| Buy |
Â
14 |
| Hold |
Â
10 |
| Sell |
Â
2 |
News Go to news feed
Alcon acquires Neurotech for $550 million and bolsters retina business with Encelto
Alcon has acquired Neurotech Pharmaceuticals for $550 million and may make additional success‑based payments. The deal adds Encelto to its retina portfolio — the only therapy approved in the U.S. for MacTel type 2 — addressing around 25,000 diagnosed patients in the U.S. Neurotech brings encapsulated cell therapies for chronic and neurodegenerative eye diseases. Alcon expects slight revenue growth in 2027 and a temporary hit to adjusted earnings per share, after which the acquisition is expected to be accretive. » More on finanzen.net
Alcon launches surgical microscope Unity M
Alcon has introduced the modular surgical microscope “Unity M” for eye surgery, which is said to provide a more stable view through an improved red reflex zone and adjustable color illumination. The device is approved in the US, Japan, Canada, India and Europe; deliveries began in September with the market launch first in the US and Japan, and later in Europe. The stock reacted with an intraday decline of around 1 percent. » More on finanzen.net
Alcon places €500 million bond at 3.875% due 2033
Alcon, through its subsidiary Alcon Finance Corporation, is issuing a five‑year €500 million bond with a 3.875% coupon. The bond will be listed on the Luxembourg Stock Exchange and traded on the Euro MTF; closing of the transaction is scheduled for 2 September. Proceeds are to be used for general corporate purposes, including wholly or partly refinancing existing debt. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 2.47B | 12.31% |
| Gross profit | 1.47B | 24.63% |
| Net profit | 0 | 100.00% |
| EBITDA | 700.97M | 35.00% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €30.4B |
Number of shares | 483.4M |
52-week high/low | €78.54 - €55.42 |
Dividend yield | 0.49% |
Dividends TTM | €0.31 |
Beta | 0.73 |
P/E ratio | 53.98 |
PEG ratio | -1.35 |
P/B ratio | 1.58 |
P/S ratio | 3.14 |
Company profile
Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
| Name | Alcon |
| CEO | David J. Endicott |
| Headquarters | Geneva,
ge Switzerland |
| Website | |
| Sector | Health Care |
| Industry | Health Care Technology |
| IPO | 04/09/2019 |
| Employees | 25,000 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | ALC |
SIX | ALC.SW |
DĂĽsseldorf | 2U3.DU |
Hamburg | 2U3.HM |
London | 0A0D.L |
MĂĽnchen | 2U3.MU |